Differential Secondary Reconstitution of In Vivo-Selected Human SCID-Repopulating Cells in NOD/SCID versus NOD/SCID/γ chainnull Mice
Figure 7
Analysis of human CD34+ cells in secondary recipient NSG mice transplanted with BM from vehicle- or 6BG/BCNU-treated mice. (a) The percentage of total human CD34 cells (%huCD34+) (b) the percentage of the human CD34+ cells that are EGFP+ (%huCD34+EGFP+) in the bone marrow were analyzed at 8 weeks after transplant into secondary recipient NSG mice by flow cytometry. The source of the bone-marrow cells that were transplanted into the secondary recipient mice were derived from vehicle- or 6BG/BCNU-treated mice primary NSG mice. *, total CD34+ cells-vehicle versus 6BG/BCNU treated; *, transduced CD34+ cells-vehicle versus 6BG/BCNU treated.
